Trial Profile
A phase II study of AQX 1125 for the treatment of chronic rhinosinusitis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs Rosiptor (Primary)
- Indications Rhinosinusitis
- Focus Adverse reactions; Therapeutic Use
- 06 Aug 2015 According to an Aquinox Pharmaceuticals media release, the company is deferring the initiation of this trial.
- 15 Oct 2014 New trial record